Latest autoimmune diseases Stories
PETACH TIKVA, Israel, Nov. 18, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Same eczema-soothing power, with a new look FORT WORTH, Texas, Nov.
- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies
- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies EAST HANOVER, N.J., Nov.
November 14 is World Diabetes Day CHICAGO, Nov.
PARIS, November 12, 2014 /PRNewswire/ -- Collaboration to generate novel diagnostic products to support personalized therapies for
NARBERTH, Pa., Nov.
Be Joint Smart to educate roughly 48,000 local residents with PsA about their disease PORTLAND, Ore., Nov.
- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014 EAST HANOVER, N.J., Nov.
ReportsnReports.com adds “Bullous Pemphigoid Global Clinical Trials Review, H2, 2014” to its store.
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.